The Federal Circuit reversed a district court ruling that found REGENXBIO's recombinant host cell claims patent ineligible under § 101, in a dispute involving genetically engineered cells used in gene therapy.
The Federal Circuit reversed a district court ruling that found REGENXBIO's recombinant host cell claims patent ineligible under § 101, in a dispute involving genetically engineered cells used in gene therapy.
